13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
about
Vaccination of adolescents with chronic medical conditions: Special considerations and strategies for enhancing uptakePoor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody TitersAssessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease.Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome.Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.
P2860
13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
13-valent pneumococcal conjuga ...... ): Results of a phase 3 study.
@en
type
label
13-valent pneumococcal conjuga ...... ): Results of a phase 3 study.
@en
prefLabel
13-valent pneumococcal conjuga ...... ): Results of a phase 3 study.
@en
P2093
P2860
P50
P356
P1476
13-valent pneumococcal conjuga ...... ): Results of a phase 3 study.
@en
P2093
Adlette Inati
Alejandra Gurtman
Anne Fiquet
Antonio Piga
Catherine Driscoll
Daniel A Scott
David C Rees
Emilio A Emini
Galila Mokhtar
Jeffrey D Lebensburger
P2860
P304
P356
10.1002/PBC.25502
P577
2015-03-23T00:00:00Z